250 related articles for article (PubMed ID: 33519217)
41. A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy.
Kozlicki MZ; Markley B; Shah NB; DeClercq J; Choi L; Zuckerman AD
Mult Scler Relat Disord; 2022 Jul; 63():103860. PubMed ID: 35609353
[TBL] [Abstract][Full Text] [Related]
42. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
Halpern R; Agarwal S; Dembek C; Borton L; Lopez-Bresnahan M
Patient Prefer Adherence; 2011 Jan; 5():73-84. PubMed ID: 21423591
[TBL] [Abstract][Full Text] [Related]
43. Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis.
Thach AV; Brown CM; Herrera V; Sasane R; Barner JC; Ford KC; Lawson KA
Int J MS Care; 2018; 20(6):251-259. PubMed ID: 30568562
[TBL] [Abstract][Full Text] [Related]
44. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
45. Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.
Zaheer R; Amin R; Riddick L; Roy S; Wolff S; Nathanson A; Newsome S
Mult Scler Relat Disord; 2023 Mar; 71():104575. PubMed ID: 36857853
[TBL] [Abstract][Full Text] [Related]
46. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
47. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States.
Nicholas J; Halpern R; Ziehn M; Peterson-Brandt J; Leszko M; Deshpande C
J Med Econ; 2020 Aug; 23(8):885-893. PubMed ID: 32338098
[No Abstract] [Full Text] [Related]
48. System-Level Variation in Multiple Sclerosis Disease-Modifying Therapy Utilization: Findings From the Multiple Sclerosis Continuous Quality Improvement Research Collaborative.
N'Dri LA; Waters DD; Walsh K; Mehta F; Oliver BJ;
Perm J; 2021 Dec; 25():. PubMed ID: 35348092
[TBL] [Abstract][Full Text] [Related]
49. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.
Bonafede MM; Johnson BH; Watson C
Clinicoecon Outcomes Res; 2013; 6():11-20. PubMed ID: 24379685
[TBL] [Abstract][Full Text] [Related]
50. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry.
Braune S; Rossnagel F; Dikow H; Bergmann A;
BMJ Open; 2021 Aug; 11(8):e042480. PubMed ID: 34344670
[TBL] [Abstract][Full Text] [Related]
51. Switching to second line MS disease-modifying therapies is associated with decreased relapse rate.
Marriott JJ; Ekuma O; Fransoo R; Marrie RA
Front Neurol; 2023; 14():1243589. PubMed ID: 37745666
[TBL] [Abstract][Full Text] [Related]
52. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
[TBL] [Abstract][Full Text] [Related]
53. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
54. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
Nicholas JA; Gudesblatt M; Garabedian M; Belviso N; Shen C; Geremakis C; Shankar SL; Mendoza JP; Lewin JB
Mult Scler Relat Disord; 2022 Jul; 63():103921. PubMed ID: 35700674
[TBL] [Abstract][Full Text] [Related]
55. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy).
Moccia M; Loperto I; Lanzillo R; Capacchione A; Carotenuto A; Triassi M; Brescia Morra V; Palladino R
BMC Health Serv Res; 2020 Aug; 20(1):797. PubMed ID: 32847587
[TBL] [Abstract][Full Text] [Related]
56. Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort.
Melesse DY; Marrie RA; Blanchard JF; Yu BN; Evans C
Patient Prefer Adherence; 2017; 11():1093-1101. PubMed ID: 28721023
[TBL] [Abstract][Full Text] [Related]
57. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
58. Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis.
Nicholas J; Zhou H; Deshpande C
Adv Ther; 2021 Jan; 38(1):758-771. PubMed ID: 33245532
[TBL] [Abstract][Full Text] [Related]
59. Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis.
Zanga G; Drzewiscki E; Tagliani P; Smietniansky M; Esnaola Y Rojas MM; Caruso D
Ther Adv Neurol Disord; 2021; 14():17562864211031099. PubMed ID: 34630632
[TBL] [Abstract][Full Text] [Related]
60. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
Yermakov S; Davis M; Calnan M; Fay M; Cox-Buckley B; Sarda S; Duh MS; Iyer R
J Med Econ; 2015; 18(9):711-20. PubMed ID: 25903661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
